In spite of this record, an FDA advisory panel voted 5-4 against approving the drug for breast cancer. While studies have shown that Avastin shrinks breast tumors, there is no evidence that it lengthens or improves the quality of patients' lives.
FDA Approves Breast Cancer Drug Avastin Despite Opposition by Advisory Panel
Concerns are growing in southern California over a cluster of “exceptionally rare” cancer cases that has...
Donald Trump announced a new package of tariffs on Tuesday, this time on generic drugs made...
